PrandiMet is a brand name of metformin/repaglinide, approved by the FDA in the following formulation(s):
PRANDIMET (metformin hydrochloride; repaglinide - tablet; oral)
Manufacturer: NOVO NORDISK INC
Approval date: June 23, 2008
Strength(s): 500MG;1MG, 500MG;2MG [RLD]
Has a generic version of PrandiMet been approved?
No. There is currently no therapeutically equivalent version of PrandiMet available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of PrandiMet. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
NIDDM regimen
Patent 6,677,358
Issued: January 13, 2004
Inventor(s): Peter Giørtz; Müller
Assignee(s): Novo Nordisk A/S
The present invention discloses a regimen for the treatment of type 2 diabetes, in which the endogenous secretion of insulin is stimulated in connection with meals, by administering a short-acting, oral hypoglycemic agent. Also, the present invention discloses a method of achieving improvement in glycemic control by combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone.Patent expiration dates:
- June 12, 2018✓✓
- June 12, 2018
See also...
- PrandiMet Consumer Information (Drugs.com)
- PrandiMet Consumer Information (Wolters Kluwer)
- PrandiMet Consumer Information (Cerner Multum)
- PrandiMet Advanced Consumer Information (Micromedex)
- Repaglinide/Metformin Consumer Information (Wolters Kluwer)
- Metformin and repaglinide Consumer Information (Cerner Multum)
- Repaglinide and metformin Advanced Consumer Information (Micromedex)
No comments:
Post a Comment